UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 8, 2003
PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 000-19756 |
| 94-3023969 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
|
|
|
|
|
34801 Campus Drive | ||||
(Address of principal executive offices) (Zip Code) | ||||
| ||||
Registrant’s telephone number, including area code: (510) 574-1400 | ||||
| ||||
Not Applicable | ||||
(Former name or former address, if changed since last report) | ||||
Item 5. Other Matters.
On July 8, 2003, Protein Design Labs, Inc. (“PDL”) announced the pricing of its convertible subordinated notes due 2023.
The foregoing matter is discussed in greater detail in PDL’s press release, a copy of which is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press Release dated July 8, 2003 regarding pricing of convertible subordinated notes due 2023. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTEIN DESIGN LABS, INC. | ||
|
| ||
Date: July 8, 2003 |
| ||
|
| ||
| By: | /s/ Sergio Garcia-Rodriguez |
|
|
| Sergio Garcia-Rodriguez | |
|
| Vice President, Legal, General Counsel and | |
3
